Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 9k
24 April 2020
Question for written answer
to the Commission
Rule 138
Clotilde Armand
 Subject: The EU’s autonomy over and leadership on health security

The COVID-19 outbreak has put the Member States’ lack of strategic preparedness for major health emergencies in the spotlight. Although the primary responsibility for health protection lies with the national healthcare systems, the EU plays an important role in preventing diseases and mitigating the danger to human health. Considering the globalised context of the epidemic, the EU needs to focus on both the internal and external dimensions of the issue.

Over the last decade, the EU has been losing ground in pharmaceutical innovation. Investment flows for research in the pharmaceutical sector have been gradually redirected to Asian countries and the USA.

What concrete initiatives can the Commission suggest to strengthen the efficiency of biopharmaceutical research in the EU and increase the EU’s ability to develop new drugs and vaccines autonomously?

On an international level, what are the next initiatives the Commission will implement to reinforce cooperation with third countries, specifically in relation to the multilateral control of disease transmission and common rapid response capabilities?

Does the Commission plan to propose an international framework for the transparency of medical experimentation and laboratory safety requirements?

Last updated: 8 May 2020Legal notice - Privacy policy